Dual Role of Hydrogen Peroxide as an Oxidant in Pneumococcal Pneumonia
- PMID: 32283950
- PMCID: PMC8035917
- DOI: 10.1089/ars.2019.7964
Dual Role of Hydrogen Peroxide as an Oxidant in Pneumococcal Pneumonia
Abstract
Significance:Streptococcus pneumoniae (Spn), a facultative anaerobic Gram-positive human pathogen with increasing rates of penicillin and macrolide resistance, is a major cause of lower respiratory tract infections worldwide. Pneumococci are a primary agent of severe pneumonia in children younger than 5 years and of community-acquired pneumonia in adults. A major defense mechanism toward Spn is the generation of reactive oxygen species, including hydrogen peroxide (H2O2), during the oxidative burst of neutrophils and macrophages. Paradoxically, Spn produces high endogenous levels of H2O2 as a strategy to promote colonization. Recent Advances: Pneumococci, which express neither catalase nor common regulators of peroxide stress resistance, have developed unique mechanisms to protect themselves from H2O2. Spn generates high levels of H2O2 as a strategy to promote colonization. Production of H2O2 moreover constitutes an important virulence phenotype and its cellular activities overlap and complement those of other virulence factors, such as pneumolysin, in modulating host immune responses and promoting organ injury. Critical Issues: This review examines the dual role of H2O2 in pneumococcal pneumonia, from the viewpoint of both the pathogen (defense mechanisms, lytic activity toward competing pathogens, and virulence) and the resulting host-response (inflammasome activation, endoplasmic reticulum stress, and damage to the alveolar-capillary barrier in the lungs). Future Directions: An understanding of the complexity of H2O2-mediated host-pathogen interactions is necessary to develop novel strategies that target these processes to enhance lung function during severe pneumonia.
Keywords: ARDS; hydrogen peroxide; pneumococci; pneumonia; pyruvate oxidase; virulence factor.
Conflict of interest statement
R.L. is inventor on patents related to the use of the TIP peptide in ARDS. The other authors have no conflict of interest.
Figures





References
-
- Anderson R and Feldman C. Review manuscript: mechanisms of platelet activation by the pneumococcus and the role of platelets in community-acquired pneumonia. J Infect 75: 473–485, 2017 - PubMed
-
- Anderson R, Steel HC, Cockeran R, von Gottberg A, de Gouveia L, Klugman KP, Mitchell TJ, and Feldman C. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J Antimicrob Chemother 60: 1155–1158, 2007 - PubMed
-
- Auzat I, Chapuy-Regaud S, Le Bras G, Dos Santos D, Ogunniyi AD, Le Thomas I, Garel JR, Paton JC, and Trombe MC. The NADH oxidase of Streptococcus pneumoniae: its involvement in competence and virulence. Mol Microbiol 34: 1018–1028, 1999 - PubMed
-
- Balakrishna S, Song W, Achanta S, Doran SF, Liu B, Kaelberer MM, Yu Z, Sui A, Cheung M, Leishman E, Eidam HS, Ye G, Willette RN, Thorneloe KS, Bradshaw HB, Matalon S, and Jordt SE. TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 307: L158–L172, 2014 - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical